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Abstract 
Aleukemic leukemia cutis (ALC), a discrete tumor of leukemic cells involving the skin, may be 
the first manifestation of acute myeloid leukemia, preceding the onset in marrow and blood 
by months and years. ALC is often difficult to diagnose and is associated with a dismal 
prognosis. A 63-year-old male presented with nodular swellings on the face, a plaque 
extending over the right shoulder and multiple enlarged cervical lymph nodes. The skin 
biopsy of the plaque lesion showed a diffuse neoplastic infiltration extending from the 
dermis to subcutaneous tissue with diffuse positivity for myeloperoxidase and focal 
positivity for CD34 on immunohistochemical staining. The diagnosis was leukemia cutis. One 
month later, acute monocytic leukemia (FAB AML-M5b) was diagnosed. The patient died on 
the seventh month of diagnosis. 
 
Introduction 
Leukemia cutis (LC) denotes the invasion of neoplastic leukocytes or their 
precursors into the epidermis, dermis, or subcutis, presenting with various cutaneous 
lesions including papules, macules, plaques, nodules, ecchymoses, palpable purpura,  
Case Rep Oncol 2011;4:547–554 
DOI: 10.1159/000334745 
Published online: 
November 22, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
548 
and ulcerative lesions [1–9]. The lesions often appear as violaceous nodules. LC is more 
common in the monocytic subtype of acute myeloid leukemia (AML). The lesions may 
be localized or disseminated, presenting at any site over the skin. In most cases of LC, 
systemic disease is already present; only 7% of cases are aleukemic. In 13% of cases of 
LC, AML is the underlying disease [10]. Aleukemic leukemia cutis (ALC) is the 
infiltration of skin by blasts prior to appearance in peripheral blood and bone marrow. 
The primary extramedullary presentation of acute leukemia is extremely rare and 
usually associated with early bone marrow relapse and poor therapy outcome [11]. The 
early recognition of the lesions of LC should be emphasized. 
Case 
A 63-year-old man was admitted to our hematology department with extensive nodular lesions on 
the trunk, submental area, forehead, scalp and a plaque extending over the right shoulder. Four 
months before admission to our department, he had been examined for swellings on the left side of 
his face and the right shoulder. On physical examination, a firm, 4-cm mass inferior to the left 
zygomatic arch, a 15-cm brown pigmented, indurated mass extending from the lateral side of 
sternocleidomastoid region to the deltoid muscle and multiple submandibular lympadenopathies 
measuring a maximum diameter of 3.5 cm were noted. At that time, his laboratory parameters were 
normal, including a complete blood count and blood chemistries. MRI scan of the face revealed a 4.2 × 
2.3 × 3.8-cm slightly lobulated mass at the inferior of the left zygomatic arch, extending from the 
nasolabial sulcus to the mandibular corpus and the lateral maxilla. Also, multiple lymphadenopathies 
with a maximal diameter of 3.4 cm were present at the submandibular, jugulodigastric regions and 
the posterior spinal accessory chain. A 15 × 10-cm mass on the right shoulder joint extending from 
the lateral side of sternocleidomastoid region to the deltoid muscle was evident on MRI. A skin biopsy 
had been obtained from the plaque lesion on the right shoulder. One month after the skin biopsy, the 
patient was evaluated for worsening malaise and fatigue. The laboratory results were as follows: 
leukocyte 46,000/mm3 (monocyte 44%, neutrophil 39%), hemoglobin 9 g/dl, platelet 64,000/mm3, 
LDH 1,109 IU/l (normal range, 240–480 IU/l). The skin biopsy of the plaque lesion showed diffuse 
neoplastic infiltration with positivity for myeloperoxidase (MPO) and CD34 on immunohistochemical 
staining. On peripheral blood smear, diffuse myeloblastic infiltration was evident (fig. 1). The bone 
marrow aspirate was hypercellular, with 22% monocytoid blasts. Immunophenotypic analysis of 
peripheral blood was positive for CD13, CD15, CD25, CD33, CD34, CD45, HLA-DR and MPO. These 
findings were compatible with acute monocytic leukemia (FAB AML-M5b). Having presented with 
skin involvement one month prior to the onset of AML-M5b, the final diagnosis was ALC. The 
remission induction regimen consisted of cytarabine 100 mg/m2 daily on days 1–7 and daunorubicin 
60 mg/m2 daily on days 1–3. On the 2nd week of chemotherapy, febrile neutropenia developed. 
Imipenem-susceptible Pseudomonas aeruginosa was grown on culture media. After seven days of 
persistent fever under imipenem, empirical antifungal treatment with amphotericin-B was added and 
was subsequently substituted by voricanozole four days later due to ongoing fever. On day 28, there 
were no myeloblasts on peripheral blood smear and bone marrow examination, but there was only 
50% regression of skin lesions. Therefore, the same chemotherapy regimen was administered for 
reinduction. On day 28 of reinduction, physical examination revealed hepatosplenomegaly, extensive 
brown pigmented nodular lesions on the trunk, submental area, forehead, scalp and a plaque 
extending over the right shoulder. Then, the patient was referred to our hematology department. The 
reexamination of the previous skin biopsy specimen revealed diffuse neoplastic infiltration extending 
from the dermis to subcutaneous tissue with diffuse positivity for MPO and focal positivity for CD34 
on immunohistochemical staining, which were findings compatible with the diagnosis of LC (fig. 2). 
On his physical examination at our clinic, progressive skin infiltrations as nodular eruptions on scalp, 
forehead and trunk and a plaque on the right shoulder were noted (fig. 3a–c). At the time of 
admission, the laboratory results were as follows: leukocyte 2,000/mm3 (monocyte 42%, neutrophil 
32%), hemoglobin 8 g/dl, platelet 76,000/mm3, serum LDH 1,335 IU/l and ESR 96 mm/h. The bone 
marrow aspirate showed 20% blastic infiltration. Histopathologic examination disclosed a 
hypercellular marrow with a medium to diffuse increase in reticulin fibers and 20% immature cells 
staining positive for MPO, CD33, CD34. Diagnosed as refractory disease, FLAG chemotherapy, a more 
aggressive regimen consisting of granulocyte colony-stimulating factor, a 5-day course of 30  
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mg/m2/day fludarabine and 2 g/m2/day cytosine arabinoside was initiated. On the 8th day of 
chemotherapy, neutropenia developed. Subsequently, urinary tract infection caused by enterococci 
was diagnosed and treated with piperacillin/tazobactam for 14 days. On the 10th day of induction 
chemotherapy, the nodular lesion on the face almost completely regressed, the pigmentation of 
nodular lesions on the trunk began to fade, and the indurated plaque on the right shoulder healed 
with hyperpigmentation (fig. 3d–f). On the 23rd day of chemotherapy, the patient developed 
neutropenic fever. Escherichia coli was isolated on blood culture and imipenem was started. Later, 
ampiric antifungal treatment with amphotericin-B was added because of ongoing fever. However, 
amphotericin-B was substituted for caspofungin for allergic reaction. On the 28th day of 
chemotherapy, LDH returned to normal and the skin infiltrates largely disappeared. However, on the 
45th day of chemotherapy, new disseminated nodular eruptions reappeared on the forehead, face and 
trunk. In addition, a 5-cm firm, endurated nodular lesion at the left submental area, a 1-cm mass at the 
left nasal cavity and a 15 × 10-cm mass on the right shoulder joint extending from the lateral side of 
sternocleidomastoid region to the deltoid muscle were detected. There was considerable venous 
distention of the right arm due to the occlusion of the right subclavian vein confirmed by venous 
Doppler USG (fig. 4). The blood count was as follows: leukocyte 4,730/mm3 (monocyte 73%, 
neutrophil 17%), hemoglobin 7 g/dl, and platelet 24,000/mm3. Peripheral blood smear revealed 92% 
myeloblasts. Serum LDH was 1,466 IU/l. Emergent chemotherapy to relieve pressure symptoms was 
initiated with cytarabine 100 mg/m2 for 7 days and idarubicin 12 mg/m2 for 3 days. On the 7th day of 
chemotherapy, febrile neutropenia was diagnosed. The blood culture was positive for Pseudomonas 
aeruginosa. Meropenem and ciprofloxacin were started. After 14 days, trimethoprim-sulphonamide 
was added for ongoing fever. On the 28th day of chemotherapy, all the skin lesions except for those on 
the trunk showed significant clinical improvement. The distention of the right arm disappeared. The 
patient had prolonged neutropenia for 3 months. The patient succumbed to his disease 6 months after 
initial diagnosis. 
Discussion 
Skin involvement in AML may present as nonspecific lesions, LC, or granulocytic 
(myeloid) sarcoma of skin and subcutis [12–17]. Nonspecific skin lesions encountered 
in AML are macules, papules, vesicles, pyoderma gangrenosum, vasculitis, neutrophilic 
dermatitis (Sweet syndrome), cutis vertices gyrata, and erythema multiforme or 
nodosum [12, 13]. Present in up to 13% of AML patients, LC is mostly associated with 
monocytic or myelomonocytic subtypes [18]. The review by Desch and Smoller [19] of 
123 skin biopsies obtained from leukemic patients showed LC to be present in 37 
(30%) patients, 23 of whom had AML or myelodysplastic syndrome. Of note, however, 
was the presence of a cutaneous process other than LC, mainly infection or drug 
reaction in the skin biopsies of AML patients. The large series by Boggs et al. [20] 
demonstrated LC to be present in 11.0 and 1.3% of patients with AML and acute 
lymphoblastic leukemia, respectively. Acute monocytic leukemia (FAB-M5) is 
disproportionately represented [20]. LC usually presents either concomitantly or after 
the diagnosis of systemic leukemia [18]. Skin involvement preceding marrow and blood 
involvement is rare [17]. 
ALC defines a rare form of leukemia in which the invasion of leukemic blasts into the 
skin occurs at least one month prior to the appearance of disease in peripheral blood or 
bone marrow [21]. Cases of ALC reported thus far show little or no harmony in their 
clinical presentation. ALC clinically presents with multiple papules, nodules, or 
infiltrated plaques with a red-brown or plum-colored surface [22]. A literature review 
showed that ALC was commonly misdiagnosed [23]. Its recognition is important 
because early diagnosis may enable a better prognosis.  
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ALC presents at least one month before peripheral blood or bone marrow 
involvement. When our case presented with nodular swellings on the face, a plaque 
extending over the right shoulder, all laboratory findings were normal. Yet, a month 
later, he was diagnosed with acute myeloid leukemia. 
In a case series of 31 ALC patients by Chang et al. [24], the most common sites of 
extramedullary involvement other than the skin were the lymph nodes (8 patients) 
followed by the spleen (2 patients). In addition to the disseminated nodular eruptions 
and the plaque lesion, our case presented with multiple enlarged cervical lymph nodes. 
Also, two months after the remission-induction therapy, his physical examination 
revealed splenomegaly. 
The diagnosis of LC requires a skin biopsy. Dense infiltrate comprising a linear array 
of pleomorphic leukemic cells in the reticular dermis with routine hematoxylin-eosin 
(H&E) staining are suggestive histological features. ALC must be distinguished by 
immunohistochemical studies from lymphoproliferative disorders. In our case, 
immunohistochemical study demonstrated positivity for CD34 and MPO, confirming the 
diagnosis of LC. 
In ALC, early marrow relapse and poor treatment response is the usual outcome. The 
mean survival time is from 3 to 30 months once leukemic cells appear in peripheral 
blood or bone marrow [22, 24]. Our patient had refractory disease and died 6 months 
after initial diagnosis. 
Patterns of skin involvement in ALC are particularly variable requiring a high degree 
of clinical suspicion. Unusual skin eruptions with nodules and plaques may be the 
presenting feature of ALC, as in our case. Early recognition of LC in aleukemic patients 
and prompt hematological treatment is key to survival. Immunohistochemistry is 
necessary to confirm the diagnosis of ALC. Because of the rarity of the disease and the 
lack of controlled studies, there is no consensus on the treatment of choice for ALC. 
Radiotherapy, chemotherapy, and total body electron therapy have yielded variable 
results [6, 22, 24–28]. 
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Fig. 1. Peripheral smear with atypical monocytoid cells (FAB AML-M5b). 
 
 
 
Fig. 2. a The skin biopsy specimen of the plaque lesion showed diffuse neoplastic infiltration in the 
dermis and subcutis (H&E, ×400). Immunohistochemical features. The infiltrated cells were diffuse 
positive for MPO (b; ×400) and focally positive for CD34 (c; ×400). 
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Fig. 3. a–c The appearance of the lesions at admission to our center after two courses of remission 
induction with cytarabine and daunorubicin. Nodular eruptions on the forehead (a), trunk (b) and a 
plaque lesion extending over the right shoulder (c). d–f The healing lesions on the 10th day of FLAG 
induction chemotherapy. The appearance of the forehead (d), trunk (e) and right shoulder (f). 
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Fig. 4. The distended right forearm due to the occlusion of the right subclavian vein by the mass on 
the right shoulder. 
 
References 
1  Husak R, Blume-Peytaki U, Orfanos C: Aleukemic leukemia cutis in an adolescent boy. N Engl J Med 
1999;340:893–894. 
2  Chang HY, Wong KM, Bosenberg M, et al: Myelogenous leukemia cutis resembling stasis dermatitis. J Am 
Acad Dermatol 2003;49:128–129. 
3  Hahn WC, Jones D, Leavitt P, et al: Leukemia cutis. Diagnosis in oncology. J Clin Oncol 1997;15:2170–
2171. 
4  Su WP, Buechner SA, Li CY: Clinicopathologic correlations in leukemia cutis. J Am Acad Dermatol 
1984;11:121–128. 
5  Baer MR, Barcos M, Farrel H, et al: Acute myelogenous leukemia with leukemia cutis. Cancer 
1989;63:2192–2200. 
6  Ohno S, Yokoo T, Ohta M, et al: Aleukemic leukemia cutis. J Am Acad Dermatol 1990;22:374–377. 
7  Longacre TA, Smoller BR: Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on 
occurrence in myelodysplastic syndromes. Am J Clin Pathol 1993;100:276–284. 
8  Bourantas K, Malamou-Mitsi VD, Christou L, et al: Cutaneous vasculitis as the initial manifestation in 
acute myelomonocytic leukemia. Ann Intern Med 1994;121:942–944. 
9  Sepp N, Radaszkiewicz T, Meijer CJL, et al: Specific skin manifestations in acute leukemia with monocytic 
differentiation. A morphologic and immunohistochemical study of 11 cases. Cancer 1993;71:124–130. 
10  Rencic A, Ramnarayanan J: Leukemia cutis. eMedicine Dermatology [last updated on Jun 7th, 2005]. 
Available from: http://www.emedicine.com/derm/topic924.htm [last accessed on Aug 24th, 2006]. 
11  Barzilai A, Lyakhovitsky A, Goldberg I, et al: Aleukemic monocytic leukemia cutis. Cutis 2002;69:301–
304. 
12  Kaiserling E, Horny H-P, Geerts M-L, Schmid U: Skin involvement in myelogenous leukemia. Morphologic 
and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol 1994;7:771.  
Case Rep Oncol 2011;4:547–554 
DOI: 10.1159/000334745 
Published online: 
November 22, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
554 
13  Longacre TA, Smoller BR: Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on 
occurrences in myelodysplastic syndromes. Am J Clin Pathol 1993;100:276–284. 
14  Shaikh BS, Frantz E, Lookingbill DP: Histologically proven leukemia cutis carries a poor prognosis in 
acute nonlymphocytic leukemia. Cutis 1987;39:57. 
15  Sipp N, Radaszkiemicz T, Meijer CJLM, et al: Specific skin manifestations in acute leukemia with 
monocytic differentiation. Cancer 1993;71:124. 
16  Baer MR, Barcos M, Farrell H, et al: Acute myelogenous leukemia in leukemia cutis. Cancer 
1989;63:2192. 
17  Long JC, Mihm MC: Multiple granulocytic tumors of the skin. Report of six cases of myelogenous 
leukemia with initial manifestations in the skin. Cancer 1977;39:2004. 
18  Ratnam KV, Khor CJ, Su WP: Leukemia cutis. Dermatol Clin 1994;12:419–431. 
19  Desch JK, Smoller BR: The spectrum of cutaneous disease in leukemias. J Cutan Pathol 1993;20:407–410. 
20  Boggs DR, Wintrobe MM, Cartwright GE: Acute leukemias: analysis of 322 cases and review of the 
literature. Medicine 1962;41:163. 
21  Horlick HP, Silvers DN, Knobler EH, Cole JT: Acute myelomonocytic leukemia presenting as a benign-
appearing cutaneous eruption. Arch Dermatol 1990;126:653–656. 
22  Okun MM, Fitzgibbon J, Nahass GT, Forsman K: Aleukemic leukemia cutis, myeloid subtype. Eur J 
Dermatol 1995;5:290–293. 
23  Wilkins R, Janes S: Aleukaemic leukaemia cutis: case report and review of the literature. Clin Lab 
Haematol 2004;26:73–75. 
24  Chang H, Shih LY, Kuo TT: Primary aleukemic myeloid leukemia cutis treated successfully with 
combination chemotherapy: report of a case and review of the literature. Ann Hematol 2003;82:435–
439. 
25  Lee B, Fatterpekar GM, Kim W, Som PM: Granulocytic sarcoma of the temporal bone. AJNR Am J 
Neuroradiol 2002;23:1497–1499. 
26  Török L, Lueff S, Garay G, Tápai M: Monocytic aleukemic leukemia cutis. J Eur Acad Dermatol Venerol 
1999;13:54–58. 
27  Tomasini C, Quaglino P, Novelli M, Fierro MT: ‘Aleukemic’ granulomatous leukemia cutis. Am J 
Dermatopathol 1998;20:417–421. 
28  Imanaka K, Fujiwara K, Satoh K, Kuroda Y, Takahashi M, Sadatoh N, et al: A case of aleukemic monocytic 
leukemia cutis treated with total body electron therapy. Radiat Med 1988;6:229–231.  